Is the S&P 500 a buying opportunity? Oppenheimer highlights 200-Day MA as a key level
Oppenheimer Asset Management pointed out that the S&P 500 (SP500) has dipped down to test its 200-day moving average, which ...
Still Holding On To Oppenheimer Holdings, As Markets Have Been In Its Favor
Oppenheimer Holdings' profit margin is lacking behind key peers, particularly Morgan Stanley, who is also a key competitor.
Oppenheimer Asset Management Inc. Sells 766 Shares of Invesco S&P 500 High Beta ETF (NYSEARCA:SPHB)
Oppenheimer Asset Management Inc. lessened its position in Invesco S&P 500 High Beta ETF (NYSEARCA:SPHB – Free Report) by ...
Oppenheimer Asset Management Inc. Acquires 298 Shares of Hess Midstream LP (NYSE:HESM)
Oppenheimer Asset Management Inc. raised its position in Hess Midstream LP (NYSE:HESM – Free Report) by 2.6% during the 4th ...
Fintel on MSN1d
Oppenheimer Initiates Coverage of Abeona Therapeutics (ABEO) with Outperform Recommendation
Fintel reports that on March 5, 2025, Oppenheimer initiated coverage of Abeona Therapeutics (NasdaqCM:ABEO) with a Outperform ...
Oppenheimer Celebrates Oscar Success Anniversary With Limited Rerelease
If you missed Oppenheimer in IMAX you can get another chance to see it this weekend with a one-week USA and Canada rerelease ...
Christopher Nolan's The Odyssey adds Shogun star to its massively star-studded cast, and I'm getting Oppenheimer vibes all over again
Shogun star Cosmo Jarvis has joined the cast of Christopher Nolan's The Odyssey - and I don't think the cast list is ever ...
The News International3d
'Oppenheimer' star David Krumholtz opens up about rare disease
David Krumholtz unfortunately developed a rare and extremely dangerous disease, and he feels the need to publicly alert ...
Olema updated palazestrant combination trial, says Oppenheimer
Oppenheimer analyst Matthew Biegler says Olema Oncology (OLMA) published a revised corporate deck today which included an update from the ...
Olema Pharmaceuticals (OLMA) Receives a Buy from Oppenheimer
Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today and set a price target of ...
Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer
Oppenheimer analyst Jay Olson lowered the firm’s price target on Denali Therapeutics (DNLI) to $42 from $50 and keeps an Outperform rating on the shares following quarterly results and after hosting ...